NewLimit is creating epigenetic reprogramming medications to cure diseases with significant unmet medical needs.
NewLimit is creating epigenetic reprogramming medications to cure diseases with significant unmet medical needs.
Biotechnology📍 South San Francisco, CAFounded 2021
Current Valuation
$1.6B
as of 2025-Q4
UNICORN
QL Price
$1.6B
0% vs last round
QuantLogix's current estimate for NewLimit, published 2026-09-27 — in line with the last disclosed round of $1.6B (2025-Q4).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$1.6B
2025-Q4
weight 0.6
Secondary market print
$1.6B
2026-06-27
weight 0.58
How this price has held up
No round has priced for NewLimit since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, NewLimit, 2026-09-27 (10f83aa02d0f6240).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is NewLimit going public?
No. NewLimit is private and has not filed to go public. There is no S-1 on file.
What is NewLimit's valuation in 2026?
NewLimit is valued at $1.6B as of 2025-Q4, set by its Early Stage VC ($45M, Oct 2025). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has NewLimit filed an S-1?
No public S-1 is on file for NewLimit.
How much has NewLimit raised?
NewLimit has raised $247.25M in total, most recently a Early Stage VC of $45M in Oct 2025.
Is NewLimit publicly traded — can you buy NewLimit stock?
No. NewLimit is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for NewLimit on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2021
HQ
South San Francisco, CA
Employees
43
Total Raised
$247.25M
Last Round
Early Stage VC — $45M (Oct 2025)
IPO Status
private
Fundraising Status
Early Stage VC · $45M · 11 mo ago
privateTotal raised $247.25M
Secondary Market
Implied price / share
$21.47
Open interest
5
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Early Stage VC
$45M
Oct 2025
—
$1.6B
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for NewLimit — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-27. Re-checked weekly.
Talent Signal
Hiring trend
▼ Hiring downtrend
-12% vs 2026-08
Open roles
15
via greenhouse
Product-build share
67%
engineering, research, product, design
Trajectory
tightening
heavy product build — 67% of open roles are product-building functions (engineering/research/product) — 9 of 15 open roles are research.
Open roles trending down; no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Lead Security & Infrastructure EngineerPrincipal/Senior Scientist, mRNA engineeringScientist, Drug Product AnalyticalScientist, LNP-Drug Product DevelopmentScientist, LNP-Lipid ChemistryScientist/Senior Scientist
Counted from NewLimit's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Clinical TrialsHealth CareBiotechnology
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q4. Refreshed quarterly.